Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: United Therapeutics Corporation, 3 years.
United Therapeutics Corporation
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 21, 2025 | United Therapeutics Corporation | Option exercise | +3,000 | $175.43 | $526,290 |
| Apr 21, 2025 | United Therapeutics Corporation | Open-market sale | −3,000 | $285.57 | $856,710 |
| Apr 14, 2025 | United Therapeutics Corporation | Option exercise | +3,000 | $175.43 | $526,290 |
| Apr 14, 2025 | United Therapeutics Corporation | Open-market sale | −3,000 | $285.16 | $855,480 |
| Apr 7, 2025 | United Therapeutics Corporation | Option exercise | +4,000 | $175.43 | $701,720 |
| Apr 7, 2025 | United Therapeutics Corporation | Open-market sale | −4,000 | $284.55 | $1,138,200 |
| Aug 2, 2024 | United Therapeutics Corporation | Option exercise | +5,000 | $175.43 | $877,150 |
| Aug 2, 2024 | United Therapeutics Corporation | Open-market sale | −900 | $320.39 | $288,351 |
| Aug 2, 2024 | United Therapeutics Corporation | Open-market sale | −900 | $321.29 | $289,161 |
| Aug 2, 2024 | United Therapeutics Corporation | Open-market sale | −900 | $326.40 | $293,760 |
| Aug 2, 2024 | United Therapeutics Corporation | Open-market sale | −1,300 | $327.96 | $426,348 |
| Aug 2, 2024 | United Therapeutics Corporation | Open-market sale | −900 | $328.99 | $296,091 |
| Aug 2, 2024 | United Therapeutics Corporation | Open-market sale | −100 | $330.39 | $33,039 |
| Apr 22, 2024 | United Therapeutics Corporation | Option exercise | +3,000 | $88.03 | $264,090 |
| Apr 22, 2024 | United Therapeutics Corporation | Sold back to the company | −3,000 | $234.06 | $702,180 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.